Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
Stock Information for Inovio Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.